Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Clinical trial NCT03708003 · TERMINATED
Trial details
- NCT number
- NCT03708003
- Sponsor
- Swiss Cancer Institute
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-11
- Primary completion
- 2025-11-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.